<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 18, 1997
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
NEW JERSEY 1-1-432 22-2429994
- ---------------------- ----------------- ---------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
-2-
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation today indicated that, as a
result of several recent developments, the Company expects to report a net loss
approximating $0.07 to $0.11 per share for the third quarter ending September
30, 1997. In addition to the one-time, pre tax charge of $1.8 million
associated with the settlement of a shareholder class action lawsuit announced
on July 31, new factors accounting for the revised outlook include: higher than
expected legal expenses associated with the settlement; a decision to increase
marketing expenditures in response to a specific product opportunity; delayed
sales of certain products due to back orders with third-party manufacturers; and
slower than expected wholesaler pull-through of ProAmatine/R/ and Agrylin/TM/.
The Company stated that it has reported an operating profit for
three consecutive quarters and given the non-recurring nature of a significant
portion of the factors impacting the third quarter, the Company expects to
resume profitability in the fourth quarter of the year.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: September 22, 1997 By: /s/ Anthony A. Rascio
------------------------------
Anthony A. Rascio
Vice President
